Stephen R Byrn
Overview
Explore the profile of Stephen R Byrn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barbosa E, Andrade M, Gubitoso M, Bezzon V, Smith P, Byrn S, et al.
Int J Pharm
. 2021 Apr;
602:120611.
PMID: 33872710
The levitation of samples in an acoustic field has been of interest in the preparation and study of amorphous solid dispersions (ASD). Here, niclosamide-polymer solutions were levitated in a multi-emitter...
12.
Bezzon V, Ferreira F, Smith P, Benmore C, Byrn S, de Araujo G
Int J Pharm
. 2021 Mar;
600:120500.
PMID: 33753163
We use X-ray pair distribution function (PDF) analysis applied to high-energy synchrotron X-ray powder diffraction data to evaluate the amorphous solid dispersions interactions and their aging stability. The obtained systems...
13.
Yu D, Seelam R, Zhang F, Byrn S, Hoag S
J Pharm Sci
. 2021 Mar;
110(7):2789-2799.
PMID: 33737019
Poly (ethylene oxide) (PEO) has been widely used in abuse-deterrent formulations (ADFs) to increase tablet hardness. Previous studies have shown that formulation variables such as processing conditions and particle size...
14.
Okezue M, Smith D, Zeller M, Byrn S, Smith P, Bogandowich-Knipp S, et al.
Acta Crystallogr C Struct Chem
. 2020 Nov;
76(Pt 11):1010-1023.
PMID: 33148877
Bedaquiline [systematic name: 1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol, CHBrNO] is one of two important new drugs for the treatment of drug-resistant tuberculosis (TB). It is marketed in the US as its fumarate salt {systematic...
15.
Yang M, Byrn S, Clase K
AAPS PharmSciTech
. 2020 Jul;
21(5):198.
PMID: 32676955
High numbers of drug recalls persist despite the tremendous time and effort invested by pharmaceutical organizations and regulatory bodies such as the Food and Drug Administration (FDA) to ensure the...
16.
Lu X, Tsutsumi Y, Huang C, Xu W, Byrn S, Templeton A, et al.
Phys Chem Chem Phys
. 2020 Jun;
22(23):13160-13170.
PMID: 32495810
Understanding the relationship between the structure and the physicochemical attributes of crystalline pharmaceuticals requires high-resolution molecular details. Solid-state nuclear magnetic resonance (ssNMR) spectroscopy is an indispensable tool for analyzing molecular...
17.
Lu X, Li M, Huang C, Lowinger M, Xu W, Yu L, et al.
Mol Pharm
. 2020 May;
17(7):2585-2598.
PMID: 32401529
Despite the wide utilization of amorphous solid dispersions (ASDs) for formulating poorly water-soluble drugs, fundamental understanding of the structural basis behind their stability and dissolution behavior is limited. This is...
18.
Lu X, Huang C, Li M, Skomski D, Xu W, Yu L, et al.
J Phys Chem B
. 2020 May;
124(25):5271-5283.
PMID: 32378905
Crystalline and amorphous materials usually possess distinct physicochemical properties due to major variations in long-range and local molecular packings. Enhanced fundamental knowledge of the molecular details of crystalline-to-amorphous interconversions is...
19.
Boyce H, Dave V, Scoggins M, Gurvich V, Smith D, Byrn S, et al.
AAPS PharmSciTech
. 2020 Jan;
21(3):86.
PMID: 31997096
The main goal of the presented work was to understand changes in the microstructure of tablets, as well as the properties of its main component viz. polyethylene oxide (PEO) as...
20.
Byrn S, Chen X, Smith P
AAPS PharmSciTech
. 2019 May;
20(5):176.
PMID: 31037517
Predictive formulation design and accelerated formulation design can lead to the discovery of useful formulations to support drug clinical studies and successful drug approval. Predictive formulation design can also lead...